Vertex Pharmaceuticals, Inc (NASDAQ: VRTX) on Friday, plunged -3.77% from the previous trading day, before settling in for the closing price of $483.96. Within the past 52 weeks, VRTX’s price has moved between $341.90 and $519.88.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 27.16% over the last five years. The company achieved an average annual earnings per share of -96.49%. With a float of $256.88 million, this company’s outstanding shares have now reached $257.70 million.
The firm has a total of 5400 workers. Let’s measure their productivity. In terms of profitability, gross margin is 86.1%, operating margin of -2.96%, and the pretax margin is 2.45%.
Vertex Pharmaceuticals, Inc (VRTX) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Vertex Pharmaceuticals, Inc is 0.26%, while institutional ownership is 92.76%. The most recent insider transaction that took place on Nov 15 ’24, was worth 7,178. Before that another transaction happened on Nov 11 ’24, when Company’s EVP & Chief Financial Officer sold 3,000 for $518.27, making the entire transaction worth $1,554,810. This insider now owns 44,137 shares in total.
Vertex Pharmaceuticals, Inc (VRTX) Recent Fiscal highlights
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported 4.2 earnings per share (EPS) for the period topping the consensus outlook (set at 4.09) by 0.11. Wall Street market experts anticipate that the next fiscal year will bring earnings of 4.46 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -96.49% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 22.10% during the next five years compared to 11.42% growth over the previous five years of trading.
Vertex Pharmaceuticals, Inc (NASDAQ: VRTX) Trading Performance Indicators
Vertex Pharmaceuticals, Inc (VRTX) is currently performing well based on its current performance indicators. A quick ratio of 2.20 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 10.87.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.99, a number that is poised to hit 4.07 in the next quarter and is forecasted to reach 18.92 in one year’s time.
Technical Analysis of Vertex Pharmaceuticals, Inc (VRTX)
Analysing the last 5-days average volume posted by the [Vertex Pharmaceuticals, Inc, VRTX], we can find that recorded value of 1.52 million was better than the volume posted last year of 1.18 million. As of the previous 9 days, the stock’s Stochastic %D was 32.49%. Additionally, its Average True Range was 13.73.
During the past 100 days, Vertex Pharmaceuticals, Inc’s (VRTX) raw stochastic average was set at 24.94%, which indicates a significant increase from 12.30% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 38.35% in the past 14 days, which was higher than the 23.66% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $476.39, while its 200-day Moving Average is $453.57. Now, the first resistance to watch is $477.72. This is followed by the second major resistance level at $489.75. The third major resistance level sits at $499.56. If the price goes on to break the first support level at $455.89, it is likely to go to the next support level at $446.08. Now, if the price goes above the second support level, the third support stands at $434.05.
Vertex Pharmaceuticals, Inc (NASDAQ: VRTX) Key Stats
Market capitalization of the company is 115.41 billion based on 257,529K outstanding shares. Right now, sales total 9,869 M and income totals 3,620 M. The company made 2,772 M in profit during its latest quarter, and 1,045 M in sales during its previous quarter.
